The stock of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) reached all time low today, Nov, 3 and still has $2.99 target or 10.00% below today’s $3.32 share price. This indicates more downside for the $59.37M company. This technical setup was reported by Barchart.com. If the $2.99 PT is reached, the company will be worth $5.94 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 44,388 shares traded hands. Catabasis Pharmaceuticals Inc (NASDAQ:CATB) has declined 33.72% since April 1, 2016 and is downtrending. It has underperformed by 34.93% the S&P500.
Analysts await Catabasis Pharmaceuticals Inc (NASDAQ:CATB) to report earnings on November, 10. They expect $-0.64 earnings per share, down 16.36% or $0.09 from last year’s $-0.55 per share. After $-0.61 actual earnings per share reported by Catabasis Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 4.92% negative EPS growth.
Catabasis Pharmaceuticals Inc (NASDAQ:CATB) Ratings Coverage
Out of 2 analysts covering Catabasis Pharmaceuticals (NASDAQ:CATB), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Catabasis Pharmaceuticals has been the topic of 4 analyst reports since August 17, 2015 according to StockzIntelligence Inc. Wedbush maintained the shares of CATB in a report on Monday, August 17 with “Buy” rating. The company was maintained on Tuesday, March 22 by Citigroup. The stock has “Outperform” rating given by Wedbush on Wednesday, June 8. The firm has “Buy” rating given on Thursday, June 9 by Citigroup.
According to Zacks Investment Research, “Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054 and CAT-2003, CAT-4001 as well as various programs which are in different clinical-stage. Catabasis Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.”
More notable recent Catabasis Pharmaceuticals Inc (NASDAQ:CATB) news were published by: Marketwatch.com which released: “Catabasis shares plummet 51% after drug trial misses goal” on April 24, 2015, also Businesswire.com with their article: “Catabasis Pharmaceuticals and Sarepta Therapeutics Announce a Joint Research …” published on September 29, 2016, Businesswire.com published: “Catabasis Pharmaceuticals to Host Investor Day in New York City on November 17” on November 03, 2016. More interesting news about Catabasis Pharmaceuticals Inc (NASDAQ:CATB) were released by: Businesswire.com and their article: “Catabasis Pharmaceuticals Announces Pricing of $10 Million Offering of Common …” published on September 23, 2016 as well as Businesswire.com‘s news article titled: “FARA Announces Catabasis Pharmaceuticals as the Recipient of the Kyle Bryant …” with publication date: January 19, 2016.
CATB Company Profile
Catabasis Pharmaceuticals, Inc., incorporated on June 26, 2008, is a clinical-stage biopharmaceutical company. The Firm is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company’s primary focus is on treatments for rare diseases. The Firm is also developing other product candidates for the treatment of lipid disorders. The Company’s CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. The Company’s CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company’s CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.